Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BIRC2 | Q13490 | 1/20 | 0.65 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | ANPEP | P15144 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | THRB | P10828 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MME | P08473 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29046832 | 1.00 | BIRC2 (0.65) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| SCHEMBL10443850 | 1.00 | BIRC2 (0.65) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| SCHEMBL23106759 | 1.00 | BIRC2 (0.65) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| Hydrochloric Acid SCHEMBL28611123 | 0.99 | BIRC2 (0.64) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| Hydrochloric Acid SCHEMBL5500035 | 0.99 | BIRC2 (0.64) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| Hydrochloric Acid SCHEMBL10443261 | 0.99 | BIRC2 (0.64) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| Hydrochloric Acid SCHEMBL5500030 | 0.99 | BIRC2 (0.64) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| Hydrochloric Acid SCHEMBL11594408 | 0.99 | BIRC2 (0.64) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| Acetic Acid SCHEMBL10444079 | 0.99 | BIRC2 (0.64) | BIRC2OPRK1LTA4HANPEPALDH1A1 | |
| Acetic Acid SCHEMBL10444077 | 0.99 | BIRC2 (0.64) | BIRC2OPRK1LTA4HANPEPALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | Design Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| CN-117279636-A | Methods and compounds for modulating myotonic muscular dystrophy type 1 | 设计治疗公司 | 2023-12-22 | — | — | CN | disclosed |
| CN-117229350-A | 4-fluoro-indoline compound and preparation method and application thereof | 曲阜师范大学 | 2023-12-15 | — | — | CN | disclosed |
| EP-4259133-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| CN-116554068-A | Preparation method of thio-polypeptide | 西安交通大学 | 2023-08-08 | — | — | CN | disclosed |
| WO-2022126000-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPHY 1 | Design Therapeutics, Inc. (US) | 2022-06-16 | — | — | WO | disclosed |
| CN-101235078-B | Method for generating amido bond | UNIV XIAMEN | 2010-08-25 | — | — | CN | disclosed |
| CN-101235078-A | Method for generating amido bond | UNIV XIAMEN (CN) | 2008-08-06 | — | — | CN | disclosed |
| EP-0350163-A2 | Renin inhibitory peptides | BEECHAM GROUP PLC (GB) | 1990-01-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240166693-A1 | METHODS AND COMPOUNDS FOR MODULATING MYOTONIC DYSTROPY 1 | MTPN, DMPK, MBNL1 | BIRC2 2397/4885OPRK1 1730/4885LTA4H 4483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.